SCHEMBL5024554

SCHEMBL5024554

Cc1ccc(CNc2ccc3c(N4CCCC4)cc(C)nc3c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 0.51
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HSD17B10 Q99714 2/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.45
HPGD P15428 1/20 0.45
CTNNB1 P35222 5/20 0.44
TCF7L2 Q9NQB0 5/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5026871 0.91 NPC1 (0.52) NCF1NPC1RAB9AKDM4EALDH1A1
SCHEMBL5024388 0.91 CTNNB1 (0.49) NCF1GAACTNNB1TCF7L2MEN1
SCHEMBL5022553 0.91 NCF1 (0.51) NCF1NPC1RAB9AKDM4EALDH1A1
SCHEMBL5028716 0.90 NCF1 (0.50) NCF1NPC1RAB9AKDM4EALDH1A1
SCHEMBL5024595 0.89 RAB9A (0.54) NCF1NPC1RAB9AKDM4EALDH1A1
SCHEMBL5024451 0.88 NCF1 (0.46) NCF1NPC1RAB9AKDM4EALDH1A1
SCHEMBL5026876 0.88 NCF1 (0.46) NCF1CTNNB1TCF7L2MEN1KMT2A
SCHEMBL5028710 0.87 NCF1 (0.48) NCF1ALDH1A1CTNNB1TCF7L2MEN1
SCHEMBL5022709 0.84 TERT (0.50) NCF1NPC1RAB9AKDM4EALDH1A1
SCHEMBL5025305 0.83 NCF1 (0.51) NCF1NPC1RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474145-B1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-04-23 EP disclosed
CN-1627945-A Quinoline derivatives as NPY antagonists HOFFMANN LA ROCHE (CH) 2005-06-15 CN disclosed
EP-1474145-A1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-6696467-B2 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2004-02-24 US disclosed
US-20030153553-A1 Quinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 US disclosed
WO-2003066055-A1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153553-A1 Quinoline derivatives NPY1R, NPY4R, GLP1R NCF1 1858/4885NPC1 172/4885RAB9A 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.